Table 1 Baseline clinical characteristics of two groups
From: Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients
Genotype-guided group (n = 99) | Non-genotype-guided group (n = 102) | p-Value | |
|---|---|---|---|
Sex (women), n (%) | 38(38.3) | 39(38.2) | 0.98 |
Age in years, median (IQR) | 80(78–83) | 81(77–84) | 0.91 |
Medical history, n (%) | |||
Ischemic stroke | 34(34.3) | 29(28.4) | 0.37 |
Hypertension | 66(66.6) | 65(63.7) | 0.66 |
Diabetes mellitus | 34(34.3) | 30(29.4) | 0.45 |
Myocardial infarction | 8(8.0) | 6(5.8) | 0.54 |
Other heart diseasesa | 28(28.2) | 26(25.4) | 0.66 |
Peripheralvascular diseases | 1(1.0) | 3(2.9) | 0.64 |
Hyperlipemia | 34(34.3) | 33(32.3) | 0.77 |
Nephropathy | 5(5.0) | 10(9.8) | 0.20 |
Current smokers | 4(4.0) | 4(3.9) | 1.00 |
Alcohol drinking | 2(2.0) | 4(3.9) | 0.71 |
ESRS (≥3), n (%) | 87(87.8) | 91(89.2) | 0.77 |
Concomitant medication, n (%) | |||
Antihypertensive agents (CCB) | 36(36.3) | 38(37.2) | 0.90 |
Proton pump inhibitors | 5(5.0) | 4(3.9) | 0.96 |
Lipid-lowering agents, n (%) | |||
Atorvastatin | 46(46.4) | 42(41.1) | 0.45 |
Rosuvastatin | 44(44.4) | 49(48.0) | 0.61 |
Pitavastatin | 9(9.1) | 11(10.8) | 0.69 |